

# MOLECULAR CANCER RESEARCH

# TABLE OF CONTENTS

## HIGHLIGHTS

**583**      **Selected Articles from This Issue**

## CANCER GENES AND NETWORKS

**585**      **ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer**  
Christopher August Lucchesi, Saisamkalpa Mantrala, Darren Tran, Neelu Batra, Avani Durve, Conner Suen, Jin Zhang, Paramita Ghosh, and Xinbin Chen

**597**      **Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1**  
Zhibin Fu, Wenqi Chen, Di Gu, Juan Li, Kai Dong, Yuying Lan, Tao Liu, Bianhong Zhang, Lei Li, Ethan Lee, Chenghua Yang, Tao P. Zhong, and Linhui Wang

## NEW HORIZONS IN CANCER BIOLOGY

**611**      **Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma**  
Zachary J. Walker, Katherine F. Vaeth, Amber Baldwin, Denis J. Ohlstrom, Lauren T. Reiman, Kady A. Dennis, Kate Matlin, Beau M. Idler, Brett M. Stevens, Neelanjan Mukherjee, and Daniel W. Sherbenou

**622**      **DR5 Disulfide Bonding Functions as a Sensor and Effector of Protein Folding Stress**

Mary E. Law, Zaafer M. Dulloo, Samantha R. Eggleston, Gregory P. Takacs, Grace M. Alexandrow, Young il Lee, Mengxiong Wang, Brian Hardy, Hanyu Su, Bianca Forsyth, Parag Das, Pran K. Datta, Chi-Wu Chiang, Abhisheak Sharma, Siva Rama Raju Kanumuri, Olga A. Guryanova, Jeffrey K. Harrison, Boaz Tirosh, Ronald K. Castellano, and Brian K. Law

## SIGNAL TRANSDUCTION AND FUNCTIONAL IMAGING

**640**      **KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma**  
Dianna H. Huisman, Deepan Chatterjee, Robert A. Svoboda, Heidi M. Vieira, Abbie S. Ireland, Sydney Skupa, James W. Askew, Danielle E. Frodyma, Luc Girard, Kurt W. Fisher, Michael S. Karet, John D. Minna, Trudy G. Oliver, and Robert E. Lewis

## TUMOR MICROENVIRONMENT AND IMMUNOBIOLOGY


**653**      **Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis**  
Shenglin Mei, Hanyu Zhang, Taghreed Hirz, Nathan Elias Jeffries, Yanxin Xu, Ninib Baryawno, Shulin Wu, Chin-Lee Wu, Akash Patnaik, Philip J. Saylor, David B. Sykes, and Douglas M. Dahl

# TABLE OF CONTENTS

## ABOUT THE COVER

Tumor-associated macrophages (TAM) are recognized for their immunosuppressive functions across cancer types. In metastatic prostate cancer, however, TAMs are not well characterized. In their study, Mei and colleagues interrogated the heterogeneous subgroups of TAMs present in metastatic prostate cancer and further evaluated how these subgroups may be targeted to improve immune checkpoint inhibition therapies. Using multiplex immunohistochemistry, single-cell RNA sequencing, and NanoString GeoMx Digital Spatial Profiling (DSP), they revealed that high-grade tumors had increased levels of CD68<sup>+</sup> and CD68<sup>+</sup>CD163<sup>+</sup> macrophages compared to low-grade tumors, with CD68<sup>+</sup> macrophages localizing more closely to tumor regions than other immune infiltrates. The cover image highlights the spatial distribution of tumor cell and immune cell regions profiled from high-grade metastatic prostate cancer using NanoString GeoMx DSP. The authors further identified four subgroups of TAMs and found that the SPP1+/TREM2+ subgroup was prominently associated with metastasis, angiogenesis, impaired antigen presentation and disease progression-free survival. SPP1+/TREM2+ macrophages were also shown to preferentially localize within the tumor, rather than peripheral normal tissue, compared to other subgroups. Interestingly, the targeting SPP1+ macrophages in combination with anti-PD-1 in mouse models significantly improved the therapeutic efficacy of ICB, highlighting the protumoral role of these TAMs in prostate cancer progression. This article can be found on page 653.

doi: 10.1158/1541-7786.MCR-23-7-CVR



**NOTICE:** This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to <https://aacrjournals.org/pages/editorial-policies#coi>.